When does Wegovy’s patent expire?
The specific expiration date depends on which type of IP protection you mean (for example, the active-ingredient drug substance vs. specific formulations or delivery methods). Patent estates around GLP-1 medicines are often split across multiple patents with different expiry dates, so there is rarely one single “Wegovy patent expiry” date.
DrugPatentWatch.com tracks patent listings by product and includes estimated expiry information derived from published patent data. You can check the current Wegovy patent expiry timelines there: DrugPatentWatch.com – Wegovy (semaglutide) [1]
Is the “patent expiry” the same as “generic availability” for Wegovy?
Not necessarily. Even after patents expire, other exclusivities or rights (such as additional patent protections, regulatory exclusivity, or patent litigation) can delay when cheaper versions can launch.
For practical purposes, the date when generic or biosimilar competitors can enter can be later than the first patent that expires, because multiple patents may still protect different aspects of the product.
What determines how soon biosimilars or generics could appear?
For Wegovy (semaglutide), entry timing is shaped by the remaining patent “coverage” in force for:
- the underlying active ingredient,
- manufacturing or formulation details,
- specific dosing regimens or delivery features (where covered),
- and any ongoing patent challenges.
Those details are best confirmed by looking at the specific patent families and expiry estimates associated with Wegovy on an up-to-date patent tracker like DrugPatentWatch.com. [1]
Where can I verify the exact Wegovy patent list and dates?
The most direct way is to pull the patent-by-patent schedule from a tracker that compiles published filings. DrugPatentWatch.com provides product-level visibility into patent status and estimated expiry timing for Wegovy. [1]
Sources
[1] https://www.drugpatentwatch.com/p/wegovy